Two drug trials may promise some relief for people who suffer migraine headaches as well as those who have cluster headaches
Amgen Inc won U.S. Food and Drug Administration approval on Thursday for the first drug in a new class designed to prevent migraine headaches in adults. The drug, Aimovig, which is given monthly by self-injection, will have a list price of $6,900 a year, or $575 a month, the company said. The price applies to both a 70 milligram and a 140 mg dose. Any discounts or rebates will depend on negotiations with health plans, Amgen spokeswoman Kristen Davis said. Some Wall Street analysts had expected a price as high as…
Anyone who has taken the time to read the ingredients on almost any processed food product in the supermarket knows that there are a whole host of weird-sounding additives on the list in addition to what you might expect.